ZYUS Stock Overview
Manufactures and distributes cannabinoid-based therapeutics and product candidates in Canada and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
ZYUS Life Sciences Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$1.03 |
| 52 Week High | CA$1.19 |
| 52 Week Low | CA$0.71 |
| Beta | 0 |
| 11 Month Change | -1.90% |
| 3 Month Change | -1.90% |
| 1 Year Change | 7.29% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -10.43% |
Recent News & Updates
Shareholder Returns
| ZYUS | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | 2.0% | -1.6% | 0.7% |
| 1Y | 7.3% | 15.9% | 10.7% |
Return vs Industry: ZYUS underperformed the Canadian Pharmaceuticals industry which returned 25.1% over the past year.
Return vs Market: ZYUS underperformed the Canadian Market which returned 11.8% over the past year.
Price Volatility
| ZYUS volatility | |
|---|---|
| ZYUS Average Weekly Movement | 8.1% |
| Pharmaceuticals Industry Average Movement | 12.3% |
| Market Average Movement | 7.9% |
| 10% most volatile stocks in CA Market | 16.7% |
| 10% least volatile stocks in CA Market | 3.0% |
Stable Share Price: ZYUS has not had significant price volatility in the past 3 months.
Volatility Over Time: ZYUS's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | n/a | Brent Zettl | www.zyus.com |
ZYUS Life Sciences Corporation manufactures and distributes cannabinoid-based therapeutics and product candidates in Canada and internationally. The company offers cannabinoid oils, softgel capsules, and topical creams. ZYUS Life Sciences Corporation was founded in 2018 and is based in Saskatoon, Canada.
ZYUS Life Sciences Corporation Fundamentals Summary
| ZYUS fundamental statistics | |
|---|---|
| Market cap | CA$73.68m |
| Earnings (TTM) | -CA$41.09m |
| Revenue (TTM) | CA$387.00k |
188.6x
P/S Ratio-1.8x
P/E RatioIs ZYUS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZYUS income statement (TTM) | |
|---|---|
| Revenue | CA$387.00k |
| Cost of Revenue | CA$2.39m |
| Gross Profit | -CA$2.00m |
| Other Expenses | CA$39.09m |
| Earnings | -CA$41.09m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.58 |
| Gross Margin | -517.31% |
| Net Profit Margin | -10,618.35% |
| Debt/Equity Ratio | 34.1% |
How did ZYUS perform over the long term?
See historical performance and comparison